Back to top
more

ANI Pharmaceuticals (ANIP)

(Delayed Data from NSDQ)

$59.20 USD

59.20
312,253

+0.25 (0.42%)

Updated Aug 14, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (80 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Apellis (APLS) Dips on Layoffs Amid Syfovre Safety Issues

by Zacks Equity Research

Apellis (APLS) plans to initiate restructuring plans to strengthen its commercial portfolio and curb cash burn.

J&J (JNJ) Seeks Full FDA Nod for Balversa in Urothelial Cancer

by Zacks Equity Research

J&J (JNJ) submits a supplemental new drug application to the FDA for full approval of Balversa to treat urothelial carcinoma.

Invivyd (IVVD) Stock Rises 18% in 3 Months: Here's Why

by Zacks Equity Research

Invivyd's (IVVD) shares rallied almost 18% over the past three months, owing to promising developments in its monoclonal antibody candidate, VYD222, designed to prevent symptomatic COVID-19 infection.

PDS Biotech's (PDSB) Shares Up 12% in a Month: Here's Why

by Zacks Equity Research

Shares of PDS Biotech (PDSB) show an upward trajectory as the company progresses toward initiating the late-stage development of its lead pipeline candidate.

ANI Pharmaceuticals, Inc. (ANIP) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

ANI (ANIP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Esperion (ESPR) Aims to Expand Key Drug Labels for Growth

by Zacks Equity Research

Esperion's (ESPR) non-statin approved drugs uptake has continued to be the growth driver since launch. However, the company is currently facing a conflict with its partner, Daiichi Sankyo, regarding milestone payments.

J&J (JNJ) Seeks Full FDA Nod for Rybrevant in Lung Cancer

by Zacks Equity Research

J&J's (JNJ) FDA filing is based on a late-stage study showing that treatment with Rybrevant plus chemotherapy improved progression-free survival in certain NSCLC patients.

What Makes ANI (ANIP) a New Strong Buy Stock

by Zacks Equity Research

ANI (ANIP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Best Momentum Stocks to Buy for August 25th

by Zacks Equity Research

ANIP, AZPN and EXTR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 25, 2023.

Here's Why You Should Add Corcept (CORT) Stock to Your Portfolio

by Zacks Equity Research

Corcept (CORT), a top-ranked stock, is witnessing incremental sales in its only marketed product, Korlym. It is also making good progress with its promising set of pipeline candidates.

New Strong Buy Stocks for August 25th

by Zacks Equity Research

ANIP, NVMI, AZPN, GRNT and CVLG have been added to the Zacks Rank #1 (Strong Buy) List on August 25, 2023.

Bionomics (BNOX) Up on Positive Updates on PTSD & SAD Candidate

by Zacks Equity Research

Bionomics (BNOX) gains as it provides updates on further development of its lead pipeline candidate, BNC210, developed for post-traumatic stress disorder and social anxiety disorder.

Humana (HUM) to Bring Enhanced Kidney Care to MA Members

by Zacks Equity Research

Humana (HUM) makes Interwell's extensive resources available to its MA members grappling with CKD and ESKD, and hence bring about better health outcomes for them.

Fulcrum (FULC) Up as FDA Lifts Clinical Hold on SCD Candidate

by Zacks Equity Research

Fulcrum's (FULC) shares surge as the FDA lifts the clinical hold it had earlier placed on its pipeline candidate FTX-6058, to treat patients with sickle cell disease.

Here's Why Momentum in ANI (ANIP) Should Keep going

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, ANI (ANIP) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Eton Pharmaceuticals, Inc. (ETON) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Eton Pharmaceuticals, Inc. (ETON) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Is Amphastar Pharmaceuticals (AMPH) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Amphastar Pharmaceuticals (AMPH) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.

ANI Pharmaceuticals, Inc. (ANIP) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

ANI (ANIP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

ANI (ANIP) Reports Q2 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

While the top- and bottom-line numbers for ANI (ANIP) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

ANI Pharmaceuticals (ANIP) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

ANI (ANIP) delivered earnings and revenue surprises of 100% and 20.41%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -248.78% and 88.48%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

ANI Pharmaceuticals (ANIP) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

ANI Pharmaceuticals' (ANIP) second-quarter 2023 performance is likely to have been driven by rising generic and rare disease product revenues.

ANI Pharmaceuticals (ANIP) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

ANI Pharmaceuticals (ANIP) closed the most recent trading day at $52.79, moving +1.15% from the previous trading session.

ANI Pharmaceuticals (ANIP) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

ANI Pharmaceuticals (ANIP) closed the most recent trading day at $51.89, moving +1.07% from the previous trading session.

Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year?

by Zacks Equity Research

Here is how ANI Pharmaceuticals (ANIP) and ImmunoGen (IMGN) have performed compared to their sector so far this year.